Out today, with @LabJacks, @isidrolauscher, @fran_muyas, we used new mouse models of spontaneous lung and colon cancer to delineate a mechanism for why many patients with DNA mismatch repair deficient (MMRd) tumors may not respond to immunotherapy 🧵1/11 https://t.co/PtqeQrhTA4

Phil and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s Knight Cancer Institute to transform the future of cancer care and set a new standard globally. Thank you to Phil and Penny Knight for their incredible generosity.

Wow, incredible, and so incredibly important, with faltering support from our govt. we are getting so close to curing and preventing previously deadly cancers, the mission to cure must continue!!

Amanda @theLundLab and Nik @Joshilabyale and I had this idea to put together a conference about the next wave of cancer immunology. We’re pretty excited about the topic, the speakers, and the venue! Come join us and let’s talk about what’s next for cancer immunology!

We are putting together an exciting program with fresh perspectives and new biology!! Come join us next year in Portugal! @DelgoffeLab @Joshilabyale 🪐⏳

I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer. https://t.co/QnIxciRE4t

Today, the American Association for Cancer Research (AACR) called on Congress to reject the Administration's nearly 40% cut to the @NIH budget and allocate a bipartisan funding increase to $51.3 billion for the agency to accelerate progress for patients. https://t.co/CG74hj2hbC

Out now in @CD_AACR and featured #AACR25, we show a combinatorial approach to overcome resistance to RAS(ON) inhibitor monotherapy in PDAC, where use of CDK4/6 inhibitor Palbociclib and CD40 agonist drives therapy-induced senescence & CD4 T cell-dependent tumor-immune equilibrium

I had a wonderful time in the Tumor Microenvironment Working Group session! #AACR25 Thanks everyone for the warm welcome and lively discussion!

"It is critically important that we raise our voices in support of innovative cancer science and medicine." @AACRPres Patricia M. LoRusso, DO, PhD (hc), FAACR, calls on the #AACR25 delegates to stand together and call on Congress to make cancer research a national priority.

Addressing Tumor Heterogeneity: Personalized Cancer Vaccines— Catherine J. Wu addressed this topic to close out the Opening Plenary Session of the AACR Annual Meeting 2025. #AACR25

Thanks, Mikala!

To learn more about some of the new models we’ve developed to deconstruct benign-to-malignant transition, please check out the very talented @LeonieQin’s poster (# LB475), session 54 no. 12 Wed morning. Her thesis work has been integral to this project!

Incredibly excited to give this lecture, thank you @AACR and @GSK! The Gertrude B. Elion Cancer Research Award has been a huge catalyst to our research and we’ve learned a lot about the mechanisms underlying benign-to-malignant transition over the past year. Will report soon!

Francis Collins resigned from NIH yesterday. He rightly pointed out that it's Human Genome Project revolutionized every aspect of biomedical research. He points out that NIH has historically been sens as high priority and non partisan. 1/

Wrapping up our final day at #AMC25! Four days of insightful discussions, collaboration, & cutting-edge research. Grateful to everyone who joined us in DR🇩🇴to share insights, engage in conversations & foster collaborations. Until next time!🐭☀️🌴

Was fantastic presenting at a joint session of @CSHL and @NorthwellHealth with @sepideh_gholami and @PeterMKWestcott on a topic that needs more forward progress; Colorectal Cancer Liver Metastases. Looking forward to future collaborations!

How does cancer immunotherapy work, and who are the best candidates? New research from CSHL and @MIT gives us some insight into the possible effectiveness of this treatment.

Excited to share our review that’s now out in @SciImmunology. We describe how DC-T cell interactions in lymph nodes specify CD8+ T cell fates and sustain anti-tumour immune responses. @stefanispranger @kochinstitute |

Excited to announce my next chapter: I'm joining @UTSWNews as the inaugural Director of the Center for Cellular Therapies and Cancer Immunology! Looking forward to building innovative #immunotherapy programs and advancing #cancerresearch with the outstanding team at UTSW. #1/3

Excited to share a major breakthrough from the lab! D&D-seq is a new technology that bridges a key gap in single-cell multi-omics/genomics : the ability to map DNA:Protein (e.g., TFs or chromatin remodellers). Led by Ivan Raimondi, Wei-Yu Chi and Sang-Ho Yoon